Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2024 4
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Low-dose Naltrexone Improves post-COVID-19 condition Symptoms.
Tamariz L, Bast E, Klimas N, Palacio A. Tamariz L, et al. Clin Ther. 2024 Mar;46(3):e101-e106. doi: 10.1016/j.clinthera.2023.12.009. Epub 2024 Jan 23. Clin Ther. 2024. PMID: 38267326
The relative hazard of improvement for those taking low-dose naltrexone was 5.04 (95% CI, 1.22-20.77; P = 0.02) compared with physical therapy alone. Both fatigue and pain were improved in patients taking low-dose naltrexone; only fatigue …
The relative hazard of improvement for those taking low-dose naltrexone was 5.04 (95% CI, 1.22-20.77; P = 0.02) compare …
Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia.
Naik H, Cooke E, Boulter T, Dyer R, Bone JN, Tsai M, Cristobal J, McKay RJ, Song X, Nacul L. Naik H, et al. BMJ Open. 2024 May 13;14(5):e085272. doi: 10.1136/bmjopen-2024-085272. BMJ Open. 2024. PMID: 38740499 Free PMC article.
A low dose of the opioid antagonist naltrexone (ie, low-dose naltrexone (LDN)) has emerged as an off-label treatment for treating fatigue and other symptoms in PCC. ...Eligible participants will be 19-69 years old, have had a confirmed or …
A low dose of the opioid antagonist naltrexone (ie, low-dose naltrexone (LDN)) has emerged as an o …
Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.
Cabanas H, Muraki K, Eaton-Fitch N, Staines DR, Marshall-Gradisnik S. Cabanas H, et al. Front Immunol. 2021 Jul 13;12:687806. doi: 10.3389/fimmu.2021.687806. eCollection 2021. Front Immunol. 2021. PMID: 34326841 Free PMC article.
Based on the benefits reported by patients on their symptoms, low dose NTX (LDN, 3.0-5.0 mg/day) treatment seems to offer some potential benefit suggesting that its effect may be targeted towards the pathomechanism of ME/CFS. As there is no literature confirm …
Based on the benefits reported by patients on their symptoms, low dose NTX (LDN, 3.0-5.0 mg/day) treatment seems to offer some …
Longitudinal Progression of Patients with Long COVID Treated in a Post-COVID Clinic: A Cross-Sectional Survey.
Hurt RT, Yadav S, Schroeder DR, Croghan IT, Mueller MR, Grach SL, Aakre CA, Gilman EA, Stephenson CR, Overgaard J, Collins NM, Lawson DK, Thompson AM, Natividad LT, Mohamed Elfadil O, Ganesh R. Hurt RT, et al. J Prim Care Community Health. 2024 Jan-Dec;15:21501319241258671. doi: 10.1177/21501319241258671. J Prim Care Community Health. 2024. PMID: 38813984 Free PMC article.
LC symptoms often cluster into phenotypes, resembling conditions such as fibromyalgia, postural orthostatic tachycardiac syndrome (POTS), and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). LC clinics have been established to best address the needs of LC patie …
LC symptoms often cluster into phenotypes, resembling conditions such as fibromyalgia, postural orthostatic tachycardiac syndrome (POTS), an …
Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone.
Löhn M, Wirth KJ. Löhn M, et al. J Transl Med. 2024 Jul 5;22(1):630. doi: 10.1186/s12967-024-05412-3. J Transl Med. 2024. PMID: 38970055 Free PMC article. Review.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease with a broad overlap of symptomatology with Post-COVID Syndrome (PCS). ...TRPM3 dysfunction in NK cells can be improved by naltrexone in vitro and ex vivo, which may explain the mo …
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease with a broad overlap of symptomatology with Pos …